Journal Abstracts

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

1

Persistently Frequent Emergency Department Utilization among Persons with Systemic Lupus Erythematosus

Lee J1,2, Lin J1, Suter LG1,3, Fraenkel L1,3. Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23777. [Epub ahead of print]

2

The heart in systemic lupus erythematosus - A comprehensive approach by cardiovascular magnetic resonance tomography

Burkard T1,2,3, Trendelenburg M3,4, Daikeler T3,5, Hess C2,3, Bremerich J3,6, Haaf P1,3, Buser P1,3, Zellweger MJ1,3. PLoS One. 2018 Oct 1;13(10):e0202105. doi: 10.1371/journal.pone.0202105. eCollection 2018.

3

Catatonia Associated With Systemic Lupus Erythematosus (SLE): A Report of 2 Cases and a Review of the Literature

Boeke A1, Pullen B1, Coppes L1, Medina M1, Cooper JJ2. Psychosomatics. 2018 Jun 27. pii: S0033-3182(18)30314-1. doi: 10.1016/j.psym.2018.06.007. [Epub ahead of print]

4

Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment

Strand V1, Berry P2, Lin X2, Asukai Y3, Punwaney R4, Ramachandran S2. Arthritis Care Res (Hoboken). 2018 Oct 15. doi: 10.1002/acr.23788. [Epub ahead of print]

5

Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis

Jackman RP1,2, Cruz GI3, Nititham J2, Triulzi DJ4,5, Barcellos LF3, Criswell LA4, Norris PJ1,2, Busch MP1,2. Lupus Sci Med. 2018 Sep 25;5(1):e000278. doi: 10.1136/lupus-2018-000278. eCollection 2018.

6

Spousal Support for Patients With Rheumatoid Arthritis: Getting the Wrong Kind Is a Pain

Pow J1, Stephenson E1, Hagedoorn M2, DeLongis A1. Front Psychol. 2018 Sep 20;9:1760. doi: 10.3389/fpsyg.2018.01760. eCollection 2018.

7

Sonography of active rheumatoid arthritis during pregnancy: a case report and literature review

Baffour FI1, McKenzie GA1, Bekele DI2, Glazebrook KN1. Radiol Case Rep. 2018 Sep 20;13(6):1233-1237. doi: 10.1016/j.radcr.2018.08.027. eCollection 2018 Dec.

8

Rheumatoid arthritis - a mathematical model

Moise N1, Friedman A2. J Theor Biol. 2018 Oct 19. pii: S0022-5193(18)30521-6. doi: 10.1016/j.jtbi.2018.10.039. [Epub ahead of print]

9

Emergent Complications of Rheumatoid Arthritis

Berman S1, Bucher J2, Koyfman A3, Long BJ4. J Emerg Med. 2018 Sep 22. pii: S0736-4679(18)30748-0. doi: 10.1016/j.jemermed.2018.07.030. [Epub ahead of print]

10

Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis

George MD1, Sauer BC1, Teng CC1, Cannon GW1, England BR1, Kerr GS1, Mikuls TR1, Baker JF1. J Rheumatol. 2018 Oct 1. pii: jrheum.180178. doi: 10.3899/jrheum.180178. [Epub ahead of print]

11

Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis

Rhee RL1, Holweg CTJ2, Wong K2, Cuthbertson D3, Carette S4, Khalidi NA5, Koening CL6, Langford CA7, McAlear CA1, Monach PA8, Moreland LW9, Pagnoux C4, Seo P10, Specks U11, Sreih AG1, Ytterberg SR12, Merkel PA13; Vasculitis Clinical Research Consortium. PLoS One. 2018 Oct 11;13(10):e0205768. doi: 10.1371/journal.pone.0205768. eCollection 2018.

12

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial

Kremer JM1, Rigby W2, Singer NG3, Birchwood C4, Gill D4, Reiss W4, Pei J4, Michalska M4. Arthritis Rheumatol. 2018 Aug;70(8):1200-1208. doi: 10.1002/art.40493. Epub 2018 Jun 14.

13

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry

Winthrop KL1, Saag K2, Cascino MD3, Pei J3, John A3, Jahreis A3, Haselkorn T3, Furst DE4. Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

14

Changes in Care After Implementing a Multifaceted Intervention to Improve Preventive Cardiology Practice in Rheumatoid Arthritis

Majka DS1, Lee JY2, Peprah YA2, Lipiszko D2, Friesema E2, Ruderman EM2, Persell SD2. Am J Med Qual. 2018 Sep 9:1062860618798719. doi: 10.1177/1062860618798719. [Epub ahead of print]

15

No Effects of Black Tea on Cognitive Decline Among Older US Men: A Prospective Cohort Study

Feng L, Langsetmo L, Yaffe K, Sun Y, Fink HA, Shikany JM, Leung PC, Lane J Alzheimers Dis. 2018;65(1):99-105. doi: 10.3233/JAD-180103. NE, Cauley JA; Osteoporotic Fractures in Men (MrOS) Study Group.

16

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis

Massey J1, Plant D2, Hyrich K2,3, Morgan AW4, Wilson AG5, Spiliopoulou A6,7, Colombo M6, McKeigue P6, Isaacs J8, Cordell H9, Pitzalis C10, Barton A11,12; BRAGGSS, MATURA Consortium. Pharmacogenomics J. 2018 Sep;18(5):657-664. doi: 10.1038/s41397-018-0040-6. Epub 2018 Aug 31.

17

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis

Harris E1, Ng B2. Eur J Rheumatol. 2018 Jul;5(2):85-91. doi: 10.5152/eurjrheum.2018.17113. Epub 2018 Feb 13.

18

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Smolen JS1, Genovese MC1, Takeuchi T1, Hyslop DL1, Macias WL1, Rooney T1, Chen L1, Dickson CL1, Riddle Camp J1, Cardillo TE1, Ishii T1, Winthrop KL1. J Rheumatol. 2018 Sep 15. pii: jrheum.171361. doi: 10.3899/jrheum.171361. [Epub ahead of print]

19

Adverse Events and Resource Use Before and After Treat to Target in Rheumatoid Arthritis:A Post-Hoc Analysis of a Randomized Controlled Trial

Solomon DH1, Yu Z1, Katz JN1,2, Bitton A3, Corrigan C1, Fraenkel L4, Harrold LR5, Smolen JS6, Losina E2, Lu B1. Arthritis Care Res (Hoboken). 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print]

20

Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis

McCulley C1, Katz P1, Trupin L1, Yelin EH1, Barton JL1. J Rheumatol. 2018 Sep 15. pii: jrheum.171339. doi: 10.3899/jrheum.171339. [Epub ahead of print]

21

Systemic Lupus Erythematosus is a Risk Factor for Complications in Total Joint Arthroplasty

Gholson JJ1, Wilkinson BG1, Brown TS1, Gao Y1, Dowdle SB1, Callaghan JJ1. Iowa Orthop J. 2018;38:183-190.

22

Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus

Keeling SO1,2,3, Vandermeer B4,5,6, Medina J4,5,6, Chatterley T4,5,6, Nevskaya T4,5,6, Pope J4,5,6, Alaburubalnabi Z4,5,6, Bissonauth A4,5,6, Touma Z4,5,6. J Rheumatol. 2018 Oct;45(10):1448-1461. doi: 10.3899/jrheum.171310. Epub 2018 Aug 15.

23

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus

Keeling SO1,2, Alabdurubalnabi Z3,4, Avina-Zubieta A3,4, Barr S3,4, Bergeron L3,4, Bernatsky S3,4, Bourre-Tessier J3,4, Clarke A3,4, Baril-Dionne A3,4, Dutz J3,4, Ensworth S3,4, Fifi-Mah A3,4, Fortin PR3,4, Gladman DD3,4, Haaland D3,4, Hanly JG3,4, Hiraki LT3,4, Hussein S3,4, Legault K3,4, Levy D3,4, Lim L3,4, Matsos M3,4, McDonald EG3,4, Medina-Rosas J3,4, Pardo Pardi J3,4, Peschken C3,4, Pineau C3,4, Pope J3,4, Rader T3,4, Reynolds J3,4, Silverman E3,4, Tselios K3,4, Suitner M3,4, Urowitz M3,4, Touma Z3,4, Vinet E3,4, Santesso N3,4. J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.

24

The Mediterranean diet, fish oil supplements and Rheumatoid arthritis outcomes: evidence from clinical trials

Petersson S1, Philippou E2, Rodomar C3, Nikiphorou E4. Autoimmun Rev. 2018 Sep 10. pii: S1568-9972(18)30217-9. doi: 10.1016/j.autrev.2018.06.007. [Epub ahead of print]

25

The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases

Jorge AM1, Lu N1, Keller SF1, Rai SK1, Zhang Y1, Choi HK1. J Rheumatol. 2018 Sep 1. pii: jrheum.171389. doi: 10.3899/jrheum.171389. [Epub ahead of print]

26

Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries

Kimsey L1, Weissman JS2, Patel A3, Drew A4, Koehlmoos T3, Sparks JA2. Semin Arthritis Rheum. 2018 Jul 18. pii: S0049-0172(18)30305-6. doi: 10.1016/j.semarthrit.2018.07.003. [Epub ahead of print]

27

Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study

Crouthamel M1, Quattrocchi E2, Watts S3, Wang S1, Berry P1, Garcia-Gancedo L3, Hamy V2, Williams RE1. JMIR Mhealth Uhealth. 2018 Sep 13;6(9):e177. doi: 10.2196/mhealth.9656.

28

Elucidating the environmental risk factors for rheumatic diseases: An umbrella review of meta-analyses

Belbasis L1, Dosis V1, Evangelou E1,2. Int J Rheum Dis. 2018 Aug;21(8):1514-1524. doi: 10.1111/1756-185X.13356.

29

Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis

Philippou E1, Nikiphorou E2. Autoimmun Rev. 2018 Sep 10. pii: S1568-9972(18)30210-6. doi: 10.1016/j.autrev.2018.05.009. [Epub ahead of print]

30

Low Persistence Rates in Rheumatoid Arthritis Patients Treated with Triple Therapy are Attributed to Adverse Drug Events Associated with Sulfasalazine

Erhardt DP1, Cannon GW2, Teng CC3, Mikuls TR4, Curtis JR5, Sauer BC3. Arthritis Care Res (Hoboken). 2018 Sep 17. doi: 10.1002/acr.23759. [Epub ahead of print]

31

Correction to: White paper: statement on conflicts of interest

Bion J1, Antonelli M2, Blanch L3, Curtis JR4, Druml C5, Du B6, Machado FR7, Gomersall C8, Hartog C9, Levy M10, Myburgh J11, Rubenfeld G12, Sprung C13. Intensive Care Med. 2018 Sep 17. doi: 10.1007/s00134-018-5373-8. [Epub ahead of print]

32

Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists

Bagel J1, Schwartzman S2. Am J Clin Dermatol. 2018 Aug 16. doi: 10.1007/s40257-018-0377-2. [Epub ahead of print]

33

Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Zuo Y1, Barbhaiya M2, Erkan D3. Curr Rheumatol Rep. 2018 Sep 10;20(11):66. doi: 10.1007/s11926-018-0775-8.

34

Factors Associated with First Thrombosis in Patients Presenting with Obstetric Antiphospholipid Syndrome in APS Alliance For Clinical Trials & International Networking (APS ACTION) Clinical Database And Repository: a retrospective study

de Jesús GR1, Sciascia S2, Andrade D3, Nascimento IS3, Rosa R3, Barbhaiya M4, Tektonidou M5, Banzato A6, Pengo V6, Ji L7, Meroni PL8, Ugarte A9, Cohen H10, Branch DW11, Andreoli L12, Belmont HM13, Fortin PR14, Petri M15, Rodriguez E16, Cervera R17, Knight JS18, Atsumi T19, Willis R20, Erkan D4, Levy RA21,22; APS ACTION. BJOG. 2018 Sep 17. doi: 10.1111/1471-0528.15469. [Epub ahead of print]

35

Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients

Xie F1,2, Yun H1,2, Levitan EB2, Muntner P2, Curtis JR1,2. Arthritis Care Res (Hoboken). 2018 Sep 3. doi: 10.1002/acr.23737. [Epub ahead of print]

36

Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores

Chernoff D1, Scott Eastman P2, Hwang CC2, Flake DD 2nd3, Wang X2, Kivitz A4, Curtis JR5. Clin Rheumatol. 2018 Aug 29. doi: 10.1007/s10067-018-4276-y. [Epub ahead of print]

37

White paper: statement on conflicts of interest

Bion J1, Antonelli M2, Blanch L3, Curtis JR4, Druml C5, Du B6, Machado FR7, Gomersall C8, Hartog C9, Levy M10, Myburgh J11, Rubenfeld G12, Sprung C13. Intensive Care Med. 2018 Sep 6. doi: 10.1007/s00134-018-5349-8. [Epub ahead of print]

38

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus

Kozora E1,2,3,4,5, Filley CM2,3,6, Erkan D4,5, Ulu? AM7,8, Vo A9, Ramon G4, Burleson A10, Zimmerman RD5, Lockshin MD4,5. Lupus. 2018 Aug 13:961203318793215. doi: 10.1177/0961203318793215. [Epub ahead of print]

39

Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology

Sciascia S1,2, Radin M1, Unlu O3, Erkan D3, Roccatello D1,2. Eur J Rheumatol. 2018 Jul;5(2):92-95. doi: 10.5152/eurjrheum.2018.17105. Epub 2018 Jan 22.

40

Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements

Golbari NM, Porter ML, Kimball AB. J Drugs Dermatol. 2018 Aug 1;17(8):886-887.

41
42

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R. J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

43

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R. Drugs Dermatol. 2018 Aug 1;17(8):863-868.

44

Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis

Gorelick J, Cantrell W, Kucera K, Veverka KA, Gooding K. J Drugs Dermatol. 2018 Aug 1;17(8):880-884.

45
46

Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment

Mori S1, Arima N2, Ito M3, Fujiyama S4, Kamo Y5, Ueki Y6. PLoS One. 2018 Aug 24;13(8):e0203084. doi: 10.1371/journal.pone.0203084. eCollection 2018.

47

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Berekmeri A1, Mahmood F2, Wittmann M3, Helliwell P4. Expert Rev Clin Immunol. 2018 Aug 17. doi: 10.1080/1744666X.2018.1512404. [Epub ahead of print]

48

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Gordon KB1, Strober B2, Lebwohl M3, Augustin M4, Blauvelt A5, Poulin Y6, Papp KA7, Sofen H8, Puig L9, Foley P10, Ohtsuki M11, Flack M12, Geng Z13, Gu Y13, Valdes JM13, Thompson EHZ14, Bachelez H15. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

49

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

50

Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

Wade R1, Grosso A2, South E3, Rothery C2, Saramago P2, Schmitt L2, Wright K3, Palmer S2. Pharmacoeconomics. 2018 Aug 16. doi: 10.1007/s40273-018-0698-2. [Epub ahead of print]

51

Rheumatoid Arthritis-Associated Orbital Vasculitis

Weber AC1, Shetlar DJ, Yen MT. Ophthalmic Plast Reconstr Surg. 2018 Aug 6. doi: 10.1097/IOP.0000000000001192. [Epub ahead of print]

52

Factors associated with preterm delivery among women with rheumatoid arthritis and juvenile idiopathic arthritis

Smith CJF1,2, Förger F3, Bandoli G4, Chambers CD4. Arthritis Care Res (Hoboken). 2018 Aug 21. doi: 10.1002/acr.23730. [Epub ahead of print]

53

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review

Emery P1, Pope JE2, Kruger K3, Lippe R4, DeMasi R5, Lula S6, Kola B7. Adv Ther. 2018 Aug 20. doi: 10.1007/s12325-018-0757-2. [Epub ahead of print]

54

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Fleischmann RM1, Alten R2, Pileckyte M3, Lobello K4, Hua SY5, Cronenberger C4, Alvarez D4, Bock AE6, Sewell KL6. Arthritis Res Ther. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y.

55

Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis

Murray E1, Ellis A1, Butylkova Y1, Skup M2, Kalabic J3, Garg V2. J Comp Eff Res. 2018 Aug 21. doi: 10.2217/cer-2017-0106. [Epub ahead of print]

56

Effects of language, insurance and race/ethnicity on measurement properties of the PROMIS Physical Function Short Form 10a in rheumatoid arthritis

Izadi Z1, Katz PP2, Schmajuk G3, Gandrup J2, Li J2, Gianfrancesco M2, Yazdany J2. Arthritis Care Res (Hoboken). 2018 Aug 12. doi: 10.1002/acr.23723. [Epub ahead of print]

57

Methotrexate Mechanism in Treatment of Rheumatoid Arthritis

Friedman B1, Cronstein B2. Joint Bone Spine. 2018 Aug 3. pii: S1297-319X(18)30181-7. doi: 10.1016/j.jbspin.2018.07.004. [Epub ahead of print]

58

Inflammatory dietary pattern and risk of developing rheumatoid arthritis in women

Sparks JA1,2, Barbhaiya M3, Tedeschi SK4,5, Leatherwood CL4,5, Tabung FK6,7, Speyer CB4, Malspeis S4, Costenbader KH4,5, Karlson EW4,5, Lu B4,5. Clin Rheumatol. 2018 Aug 14. doi: 10.1007/s10067-018-4261-5. [Epub ahead of print]

59

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis

Tanaka Y1, McInnes IB2, Taylor PC3, Byers NL4, Chen L4, de Bono S4, Issa M4, Macias WL4, Rogai V4, Rooney TP4, Schlichting DE4, Zuckerman SH4, Emery P5. Arthritis Rheumatol. 2018 Jul 29. doi: 10.1002/art.40680. [Epub ahead of print]

60

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Zhao S1, Chadwick L1, Mysler E2, Moots RJ3.Author informationCurr Rheumatol Rep. 2018 Aug 9;20(10):57. doi: 10.1007/s11926-018-0769-6.

61

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort

Choi MY1, Clarke AE1, St Pierre Y2, Hanly JG3, Urowitz MB4, Romero-Diaz J5, Gordon C6, Bae SC7, Bernatsky S8, Wallace DJ9, Merrill JT10, Isenberg DA11, Rahman A11, Ginzler EM12, Petri M13, Bruce IN14, Dooley MA15, Fortin PR16, Gladman DD4, Sanchez-Guerrero J17, Steinsson K18, Ramsey-Goldman R19, Khamashta MA20, Aranow C21, Alarcón GS22, Manzi S23, Nived O24, Zoma AA25, van Vollenhoven RF26, Ramos-Casals M27, Ruiz-Irastorza G28, Lim SS29, Kalunian KC30, Inanc M31, Kamen DL32, Peschken CA33, Jacobsen S34, Askanase A35, Stoll T36, Buyon J37, Mahler M38, Fritzler MJ1. Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print]

62

Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions

Nowell WB1, Curtis JR2, Crow-Hercher R3. Med Care. 2018 Aug 2. doi: 10.1097/MLR.0000000000000814. [Epub ahead of print]

63

Exercise for rheumatoid arthritis of the hand

Williams MA1, Srikesavan C, Heine PJ, Bruce J, Brosseau L, Hoxey-Thomas N, Lamb SE. Cochrane Database Syst Rev. 2018 Jul 31;7:CD003832. doi: 10.1002/14651858.CD003832.pub3.

64

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Cohen SB1, Alten R2, Kameda H3, Hala T4, Radominski SC5, Rehman MI6, Palaparthy R7, Schumacher K8, Schmitt S8, Hua SY7, Ianos C9, Sewell KL10. Arthritis Res Ther. 2018 Jul 27;20(1):155. doi: 10.1186/s13075-018-1646-4.

65

A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

Maniadakis N1, Toth E2, Schiff M3, Wang X4, Nassim M4, Szegvari B5, Mountian I5, Curtis JR6. Adv Ther. 2018 Aug 4. doi: 10.1007/s12325-018-0759-0. [Epub ahead of print]

66

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis

Harrold LR1, Reed GW1, John A2, Barr CJ3, Soe K3, Magner R4, Saunders KC3, Ruderman EM5, Haselkorn T2, Greenberg JD6, Gibofsky A7, Harrington JT8, Kremer JM9. Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

67

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database

Clowse MEB1, Scheuerle AE2, Chambers C3, Afzali A4, Kimball AB5, Cush JJ6, Cooney M7, Shaughnessy L7, Vanderkelen M8, Förger F9. Arthritis Rheumatol. 2018 Apr 5. doi: 10.1002/art.40508. [Epub ahead of print]

68

Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations

West SG1. Curr Opin Rheumatol. 2018 May;30(3):243-248. doi: 10.1097/BOR.0000000000000489.

69

Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review

Ford AR1, Siegel M2, Bagel J3, Cordoro KM4,5, Garg A6, Gottlieb A7,8, Green LJ9, Gudjonsson JE10, Koo J4, Lebwohl M11, Liao W4, Mandelin AM 2nd12, Markenson JA13, Mehta N14, Merola JF15, Prussick R9, Ryan C16, Schwartzman S13, Siegel EL17,18, Van Voorhees AS19, Wu JJ20, Armstrong AW1. JAMA Dermatol. 2018 Jun 20. doi: 10.1001/jamadermatol.2018.1412. [Epub ahead of print]

70

The Effect of Pre-appointment Consult Triage on Patient Selection and Revenue Generation in a University Rheumatology Practice

West SG1, Pearson DW1, Striebich CC1, Goecker R1, Kolfenbach JR1. Arthritis Care Res (Hoboken). 2018 Jul 12. doi: 10.1002/acr.23701. [Epub ahead of print]

71

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire

Robson JC#1,2, Dawson J#3, Doll H4, Cronholm PF5, Milman N6, Kellom K7, Ashdown S8, Easley E9, Gebhart D10, Lanier G11, Mills J12, Peck J8, Luqmani RA13, Shea J14, Tomasson G15, Merkel PA16. Ann Rheum Dis. 2018 Aug;77(8):1157-1164. doi: 10.1136/annrheumdis-2017-212713. Epub 2018 Apr 25.

72

Metabolic pathways and immunometabolism in rare kidney diseases

Grayson PC1,2, Eddy S3,4, Taroni JN2,5, Lightfoot YL1, Mariani L3,4, Parikh H2,6, Lindenmeyer MT7, Ju W3,4, Greene CS2,5, Godfrey B3,4, Cohen CD7, Krischer J2,6, Kretzler M3,4, Merkel PA2,8; Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network. Ann Rheum Dis. 2018 Aug;77(8):1226-1233. doi: 10.1136/annrheumdis-2017-212935. Epub 2018 May 3.

73

Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis

Mandelin AM 2nd1, Homan PJ1, Shaffer AM1, Cuda CM1, Dominguez ST1, Bacalao E1, Carns M1, Hinchcliff M1, Lee J1, Aren K1, Thakrar A1, Montgomery AB1, Bridges SL Jr2, Bathon JM3, Atkinson JP4, Fox DA5, Matteson EL6, Buckley CD7, Pitzalis C8, Parks D4, Hughes LB2, Geraldino-Pardilla L3, Ike R5, Phillips K5, Wright K6, Filer A7, Kelly S8, Ruderman EM1, Morgan V1, Abdala-Valencia H1, Misharin AV1, Budinger GS1, Bartom ET1, Pope RM1, Perlman H1, Winter DR1. Arthritis Rheumatol. 2018 Jun;70(6):841-854. doi: 10.1002/art.40453. Epub 2018 May 3.

74

Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis

Wells AF1, Greenwald M2, Bradley JD3, Alam J3, Arora V3, Kartman CE4. Rheumatol Ther. 2018 Jun;5(1):43-55. doi: 10.1007/s40744-018-0110-x. Epub 2018 Apr 21.

75

Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis

Quinn KA1,2, Ahlman MA3, Malayeri AA3, Marko J3, Civelek AC3, Rosenblum JS2, Bagheri AA2, Merkel PA4, Novakovich E2, Grayson PC2. Ann Rheum Dis. 2018 Aug;77(8):1165-1171. doi: 10.1136/annrheumdis-2018-213102. Epub 2018 Apr 17.

76

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Berti A1, Warner R2, Johnson K2, Cornec D3, Schroeder D4, Kabat B4, Langford CA5, Hoffman GS5, Fervenza FC4, Kallenberg CGM6, Seo P7, Spiera R8, St Clair EW9, Brunetta P10, Stone JH11, Merkel PA12, Specks U4, Monach PA13; RAVE-ITN Research Group. Arthritis Rheumatol. 2018 Jul;70(7):1114-1121. doi: 10.1002/art.40471. Epub 2018 May 7.

77

Lupus community panel proposals for optimising clinical trials: 2018

Merrill JT1, Manzi S2, Aranow C3, Askenase A4, Bruce I5, Chakravarty E1, Chong B6, Costenbader K7, Dall'Era M8, Ginzler E9, Hanrahan L10, Kalunian K11, Merola J7, Raymond S12, Rovin B13, Saxena A14, Werth VP15. Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018.

78

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort

Little J1,2, Parker B2, Lunt M1, Hanly JG3, Urowitz MB4, Clarke AE5, Romero-Diaz J6, Gordon C7,8, Bae SC9, Bernatsky S10, Wallace DJ11, Merrill JT12, Buyon J13, Isenberg DA14, Rahman A14, Ginzler EM15, Petri M16, Dooley MA17, Fortin P18, Gladman DD4, Steinsson K19, Ramsey-Goldman R20, Khamashta MA21, Aranow C22, Mackay M22, Alarcón GS23, Manzi S24, Nived O25, Jönsen A25, Zoma AA26, van Vollenhoven RF27, Ramos-Casals M28, Ruiz-Irastorza G29, Sam Lim S30, Kalunian KC31, Inanc M32, Kamen DL33, Peschken CA34, Jacobsen S35, Askanase A36, Sanchez-Guerrero J37, Bruce IN1,2. Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

79

Role of macrophage migration inhibitory factor in granulomatosis with polyangiitis

Sreih AG1, Ezzedine R2, Leng L3, Fan J3, Yao J3, Reid D3, Piecychna M3, Carette S4, Cuthbertson D5, Dellaripa P6, Hoffman GS7, Khalidi NA8, Koening CL9, Langford CA7, Mahr A10, McAlear CA1, Maksimowicz-Mckinnon K11, Monach PA12, Seo P13, Specks U14, St Clair W15, Stone JH16, Ytterberg SR14, Edberg J17, Merkel PA1,18, Bucala R3. Arthritis Rheumatol. 2018 Jun 28. doi: 10.1002/art.40655. [Epub ahead of print]

80

Arterial lesions in giant cell arteritis: A longitudinal study

Kermani TA1, Diab S2, Sreih AG3, Cuthbertson D4, Borchin R4, Carette S5, Forbess L6, Koening CL7, McAlear CA3, Monach PA8, Moreland L9, Pagnoux C5, Seo P10, Spiera RF11, Warrington KJ12, Ytterberg SR12, Langford CA13, Merkel PA14, Khalidi NA2; Vasculitis Clinical Research Consortium. Semin Arthritis Rheum. 2018 May 9. pii: S0049-0172(18)30094-5. doi: 10.1016/j.semarthrit.2018.05.002. [Epub ahead of print]

81

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study

van der Heijde D1, Braun J2, Rudwaleit M3, Purcaru O4, Kavanaugh AF5. RMD Open. 2018 Apr 9;4(1):e000659. doi: 10.1136/rmdopen-2018-000659. eCollection 2018.

82

Arthroscopic-Assisted Latissimus Dorsi Tendon Transfer for Massive Rotator Cuff Tears: A Systematic Review

Memon M1, Kay J1, Quick E2, Simunovic N3, Duong A1, Henry P4, Ayeni OR1. Orthop J Sports Med. 2018 Jun 11;6(6):2325967118777735. doi: 10.1177/2325967118777735. eCollection 2018 Jun.

83

Incident fracture is associated with a period of accelerated loss of hip BMD: the Study of Osteoporotic Fractures

Christiansen BA1, Harrison SL2, Fink HA3, Lane NE4; Study of Osteoporotic Fractures Research Group. Osteoporos Int. 2018 Jul 10. doi: 10.1007/s00198-018-4606-6. [Epub ahead of print]

84

Earlier anterior cruciate ligament reconstruction is associated with a decreased risk of medial meniscal and articular cartilage damage in children and adolescents: a systematic review and meta-analysis

Kay J1, Memon M1, Shah A2, Yen YM3, Samuelsson K4, Peterson D1, Simunovic N5, Flageole H6, Ayeni OR7. Knee Surg Sports Traumatol Arthrosc. 2018 Jun 6. doi: 10.1007/s00167-018-5012-5. [Epub ahead of print]

85

The involvement of Toll-like receptor 9 in the pathogenesis of erosive autoimmune arthritis

Fischer A1, Abdollahi-Roodsaz S2,3, Böhm C1, Niederreiter B1, Meyer B1, Yau ACY4, Lönnblom E4, Joosten LAB2, Koenders M2, Lehmann CHK5, Dudziak D5, Krönke G6, Holmdahl R4, Steiner G1,7. J Cell Mol Med. 2018 Jul 11. doi: 10.1111/jcmm.13735. [Epub ahead of print]

86

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Robson JC1,2, Tomasson G1,2, Milman N1,2, Ashdown S1,2, Boonen A1,2, Casey GC1,2, Cronholm PF1,2, Cuthbertson D1,2, Dawson J1,2, Direskeneli H1,2, Easley E1,2, Kermani TA1,2, Farrar JT1,2, Gebhart D1,2, Lanier G1,2, Luqmani RA1,2, Mahr A1,2, McAlear CA1,2, Peck J1,2, Shea B1,2, Shea JA1,2, Sreih AG1,2, Tugwell PS1,2, Merkel PA3,4. J Rheumatol. 2017 Oct;44(10):1529-1535. doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.

87

Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016

Sreih AG1,2, Alibaz-Oner F1,2, Kermani TA1,2, Aydin SZ1,2, Cronholm PF1,2, Davis T1,2, Easley E1,2, Gul A1,2, Mahr A1,2, McAlear CA1,2, Milman N1,2, Robson JC1,2, Tomasson G1,2, Direskeneli H1,2, Merkel PA3,4. J Rheumatol. 2017 Dec;44(12):1933-1937. doi: 10.3899/jrheum.161467. Epub 2017 Sep 1.

88

Cervical Epidural Injection in the Management of Refractory Pain and Stiffness in Spondyloarthropathy: A Case Report Series

Gungor S1, Aiyer R2, Erkan D3. Pain Pract. 2018 Apr;18(4):532-538. doi: 10.1111/papr.12616. Epub 2017 Nov 20.

89

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis

Harrold LR1, Reed GW1, John A2, Barr CJ3, Soe K3, Magner R4, Saunders KC3, Ruderman EM5, Haselkorn T2, Greenberg JD6, Gibofsky A7, Harrington JT8, Kremer JM9. Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

90

Non-classical monocytes as mediators of tissue destruction in arthritis

Puchner A1, Saferding V1, Bonelli M1, Mikami Y2, Hofmann M1, Brunner JS1, Caldera M3, Goncalves-Alves E1, Binder NB1, Fischer A1, Simader E1, Steiner CW1, Leiss H1, Hayer S1, Niederreiter B1, Karonitsch T1, Koenders MI4, Podesser BK5, O'Shea JJ2, Menche J3, Smolen JS1, Redlich K1, Blüml S1,6. Ann Rheum Dis. 2018 Jun 29. pii: annrheumdis-2018-213250. doi: 10.1136/annrheumdis-2018-213250. [Epub ahead of print]

91

Role of macrophage migration inhibitory factor in granulomatosis with polyangiitis

Sreih AG1, Ezzedine R2, Leng L3, Fan J3, Yao J3, Reid D3, Piecychna M3, Carette S4, Cuthbertson D5, Dellaripa P6, Hoffman GS7, Khalidi NA8, Koening CL9, Langford CA7, Mahr A10, McAlear CA1, Maksimowicz-Mckinnon K11, Monach PA12, Seo P13, Specks U14, St Clair W15, Stone JH16, Ytterberg SR14, Edberg J17, Merkel PA1,18, Bucala R3. Arthritis Rheumatol. 2018 Jun 28. doi: 10.1002/art.40655. [Epub ahead of print]

92

Arterial lesions in giant cell arteritis: A longitudinal study

Kermani TA1, Diab S2, Sreih AG3, Cuthbertson D4, Borchin R4, Carette S5, Forbess L6, Koening CL7, McAlear CA3, Monach PA8, Moreland L9, Pagnoux C5, Seo P10, Spiera RF11, Warrington KJ12, Ytterberg SR12, Langford CA13, Merkel PA14, Khalidi NA2; Vasculitis Clinical Research Consortium. Semin Arthritis Rheum. 2018 May 9. pii: S0049-0172(18)30094-5. doi: 10.1016/j.semarthrit.2018.05.002. [Epub ahead of print]

93

Fluid Extravasation in Shoulder Arthroscopic Surgery: A Systematic Review

Memon M1, Kay J1, Gholami A2, Simunovic N3, Ayeni OR4. Orthop J Sports Med. 2018 May 14;6(5):2325967118771616. doi: 10.1177/2325967118771616. eCollection 2018 May.

94

Arthroscopic-Assisted Latissimus Dorsi Tendon Transfer for Massive Rotator Cuff Tears: A Systematic Review

Memon M1, Kay J1, Quick E2, Simunovic N3, Duong A1, Henry P4, Ayeni OR1. Orthop J Sports Med. 2018 Jun 11;6(6):2325967118777735. doi: 10.1177/2325967118777735. eCollection 2018 Jun.

95

Earlier anterior cruciate ligament reconstruction is associated with a decreased risk of medial meniscal and articular cartilage damage in children and adolescents: a systematic review and meta-analysis

Kay J1, Memon M1, Shah A2, Yen YM3, Samuelsson K4, Peterson D1, Simunovic N5, Flageole H6, Ayeni OR7. Knee Surg Sports Traumatol Arthrosc. 2018 Jun 6. doi: 10.1007/s00167-018-5012-5. [Epub ahead of print]

96

Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options

Strauß R1, Rose T1, Flint SM2, Klotsche J3, Häupl T1, Peck-Radosavljevic M4, Yoshida T5, Kyogoku C6, Flechsig A1, Becker AM7, Dao KH7, Radbruch A3, Burmester GR1, Lyons PA2, Davis LS7, Hiepe F1, Grützkau A3, Biesen R8. J Mol Med (Berl). 2017 Jul;95(7):753-765. doi: 10.1007/s00109-017-1515-7. Epub 2017 Mar 29.

97

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody Positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository

Unlu O1, Erkan D2, Barbhaiya M2, Andrade D3, Nascimento I3, Rosa R3, Banzato A4, Pengo V4, Ugarte A5, Gerosa M6, Ji L7, Efthymiou M8, Branch DW9, de Jesus GR10, Tincani A11, Belmont HM12, Fortin PR13, Petri M14, Rodriguez E15, Pons-Estel GJ16, Knight JS17, Atsumi T18, Willis R19, Zuily S20, Tektonidou MG21; TheBehalf of APS ACTION. Arthritis Care Res (Hoboken). 2018 Apr 18. doi: 10.1002/acr.23584. [Epub ahead of print]

98

The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients

Rodríguez-Pintó I1, Espinosa G1, Erkan D2, Shoenfeld Y3, Cervera R1; CAPS Registry Project Group. Rheumatology (Oxford). 2018 Apr 11. doi: 10.1093/rheumatology/key082. [Epub ahead of print]

99

Treatment of antiphospholipid syndrome beyond anticoagulation

Dobrowolski C1, Erkan D2. Clin Immunol. 2018 Mar 3. pii: S1521-6616(18)30119-0. doi: 10.1016/j.clim.2018.03.001. [Epub ahead of print]

100

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy

Jackson WG1, Oromendia C2, Unlu O3, Erkan D4, DeSancho MT5; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Collaborators (55) Blood Adv. 2017 Nov 16;1(25):2320-2324. doi: 10.1182/bloodadvances.2017008185. eCollection 2017 Nov 28.

101

Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction

Danila MI, Melnick JA, Curtis JR, Menachemi N, Saag KG. J Clin Rheumatol. 2018 Apr;24(3):116-121. doi: 10.1097/RHU.0000000000000620.

102

Defining and characterizing sustained remission in patients with rheumatoid arthritis

Curtis JR1, Trivedi M2, Haraoui B3, Emery P4, Park GS2, Collier DH2, Aras GA2, Chung J2. Clin Rheumatol. 2018 Apr;37(4):885-893. doi: 10.1007/s10067-017-3923-z. Epub 2017 Dec 9.

103

Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study

Curtis JR1,2, Xie F1, Chen L1, Saag KG1,2, Yun H1,2, Muntner P2. Ann Rheum Dis. 2018 Mar;77(3):386-392. doi: 10.1136/annrheumdis-2017-211727. Epub 2017 Dec 21.

104

Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study

Roblin DW1,2, Cram P3,4,5, Lou Y6, Edmonds SW3,7, Hall SF7, Jones MP6, Saag KG8, Wright NC8,9, Wolinsky FD3,7,10; PAADRN Investigators. Collaborators (5) Curtis JR, Morgan SL, Schlechte JA, Williams JH, Zelman DJ. Arch Osteoporos. 2018 Jan 6;13(1):4. doi: 10.1007/s11657-017-0402-8.

105

Hip fracture trends in the United States, 2002 to 2015

Michael Lewiecki E1, Wright NC2, Curtis JR3, Siris E4, Gagel RF5, Saag KG3, Singer AJ6,7, Steven PM8, Adler RA9,10. Osteoporos Int. 2018 Mar;29(3):717-722. doi: 10.1007/s00198-017-4345-0. Epub 2017 Dec 27.

106

Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis

Bartlett SJ1,2, Gutierrez AK3,4, Butanis A3, Bykerk VP5, Curtis JR6, Ginsberg S7, Leong AL8, Lyddiatt A9, Nowell WB7, Orbai AM3, Smith KC10, Bingham CO 3rd3. Qual Life Res. 2018 May 24. doi: 10.1007/s11136-018-1880-x. [Epub ahead of print]

107

Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians

Jagpal A1, Curtis JR2. Drug Saf. 2018 Jun;41(6):545-553. doi: 10.1007/s40264-018-0639-1.

108

Evaluation of a Methodological Approach to Define An Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data

Curtis JR1,2, Xie F1, Chen L1, Greenberg JD3, Zhang J2. Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23533. [Epub ahead of print]

109

Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial

Danila MI1, Outman RC1, Rahn EJ1, Mudano AS1, Redden DT1, Li P1, Allison JJ2, Anderson FA2, Wyman A2, Greenspan SL3, LaCroix AZ4,5, Nieves JW6, Silverman SL7, Siris ES8, Watts NB9, Miller MJ10, Curtis JR1, Warriner AH1, Wright NC1, Saag KG1. J Bone Miner Res. 2018 May;33(5):763-772. doi: 10.1002/jbmr.3395. Epub 2018 Feb 26.

110

Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors

Beukelman T1, Xie F2, Chen L2, Horton DB3, Lewis JD4, Mamtani R4, Mannion MM1, Saag KG2, Curtis JR2. Ann Rheum Dis. 2018 Feb 9. pii: annrheumdis-2017-212613. doi: 10.1136/annrheumdis-2017-212613. [Epub ahead of print]

111

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis

Pearce FA1,2, Craven A3, Merkel PA4, Luqmani RA3, Watts RA5,6. Rheumatology (Oxford). 2017 Nov 1;56(11):1962-1969. doi: 10.1093/rheumatology/kex293.

112

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials

Moots RJ1, Sebba A2, Rigby W3, Ostor A4, Porter-Brown B5, Donaldson F5, Dimonaco S5, Rubbert-Roth A6, van Vollenhoven R7, Genovese MC8. Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370.

113

The combination of three autoantibodies, ACPA, RF and anti-CarP antibodies is highly specific for rheumatoid arthritis: implications for very early identification of individuals at risk to develop rheumatoid arthritis

Verheul MK1, Böhringer S2, van Delft MAM1, Jones JD3, Rigby WFC3, Gan RW4, Holers VM5, Edison JD6, Deane KD5, Janssen KMJ7, Westra J8, Brink M9, Rantapää-Dahlqvist S9, Huizinga TWJ1, van der Helm-van Mil AHM1, van der Woude D1, Toes REM1, Trouw LA1,10. Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40562. [Epub ahead of print]

114

Treatment algorithms for systemic sclerosis according to experts

Fernández-Codina A1,2, Walker KM3, Pope JE1; Scleroderma Algorithm Group. Collaborators (47) Hughes M, van den Hoogen FH, Vonk M, Valentini G, Tafazzul-E-Haque M, Proudman SM, Mayes MD, Baron M, Orzechowski N, Simeón-Aznar CP, Francesca I, Hsu V, Seibold JR, Steen V, Murdaca G, Walker UA, Silver RM, Pauling JD, Larché M, Khalidi N, Merkel PA, Koenig M, Lally T, Gordon J, Fortin PR, Hayat S, Masetto A, Jacobsen S, Walker J, Denton C, Hesselstrand R, Gabrielli A, Wigley FM, Hunzelmann N, Castelino FV, Douglas Smith C, Johnson SR, Farge D, Boin F, Chung L, Furst DE, Clements P, Vacca A, Riccieri V, Shah A, Inanc M, Nevskaya T. Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40560. [Epub ahead of print]

115

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Gladman D1, Rigby W1, Azevedo VF1, Behrens F1, Blanco R1, Kaszuba A1, Kudlacz E1, Wang C1, Menon S1, Hendrikx T1, Kanik KS1. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.

116

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire

Robson JC#1,2, Dawson J#3, Doll H4, Cronholm PF5, Milman N6, Kellom K7, Ashdown S8, Easley E9, Gebhart D10, Lanier G11, Mills J12, Peck J8, Luqmani RA13, Shea J14, Tomasson G15, Merkel PA16. Ann Rheum Dis. 2018 Apr 25. pii: annrheumdis-2017-212713. doi: 10.1136/annrheumdis-2017-212713. [Epub ahead of print]

117

Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Berti A1, Warner R2, Johnson K2, Cornec D3, Schroeder D4, Kabat B4, Langford CA5, Hoffman GS5, Fervenza FC4, Kallenberg CGM6, Seo P7, Spiera R8, St Clair EW9, Brunetta P10, Stone JH11, Merkel PA12, Specks U4, Monach PA13; RAVE-ITN Research Group. Arthritis Rheumatol. 2018 Apr 25. doi: 10.1002/art.40471. [Epub ahead of print]

118

Pharmacogenomic Primer for the Pediatrician-What Is Really Important?

Manzi S. Pediatr Ann. 2018 May 1;47(5):e217-e219. doi: 10.3928/19382359-20180429-01.

119

Lupus community panel proposals for optimising clinical trials: 2018

Merrill JT1, Manzi S2, Aranow C3, Askenase A4, Bruce I5, Chakravarty E1, Chong B6, Costenbader K7, Dall'Era M8, Ginzler E9, Hanrahan L10, Kalunian K11, Merola J7, Raymond S12, Rovin B13, Saxena A14, Werth VP15. Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018.

120

Metabolic pathways and immunometabolism in rare kidney diseases

Grayson PC1,2, Eddy S3,4, Taroni JN2,5, Lightfoot YL1, Mariani L3,4, Parikh H2,6, Lindenmeyer MT7, Ju W3,4, Greene CS2,5, Godfrey B3,4, Cohen CD7, Krischer J2,6, Kretzler M3,4, Merkel PA2,8; Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network. Ann Rheum Dis. 2018 May 3. pii: annrheumdis-2017-212935. doi: 10.1136/annrheumdis-2017-212935. [Epub ahead of print]

121

Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients

Kan HJ1, Dyagilev K2, Schulam P3, Saria S3, Kharrazi H4, Bodycombe D4, Molta CT5, Curtis JR6. Arthritis Res Ther. 2018 May 2;20(1):79. doi: 10.1186/s13075-018-1580-5.

122

Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient Reported Outcome Data Collection: A Qualitative Study

Navarro-Millán I1,2, Zinski A3, Shurbaji S4, Johnson B4, Fraenkel L5, Willig J4, Danila MI6, Yun H7, Curtis JR6, Safford MM1. Arthritis Care Res (Hoboken). 2018 Apr 18. doi: 10.1002/acr.23580. [Epub ahead of print]

123

A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials

Boers M1, Singh JA2,3,4, Cofield SS5, Louis Bridges S Jr5, Moreland LW6, O'Dell JR7, Wu H8, Leatherman S8, Curtis JR5. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23590. [Epub ahead of print]

124

Obesity and response to anti-tumor necrosis factor-? agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis

Singh S1,2, Facciorusso A3, Singh AG4, Casteele NV1, Zarrinpar A1,5,6, Prokop LJ7, Grunvald EL8, Curtis JR9, Sandborn WJ1. PLoS One. 2018 May 17;13(5):e0195123. doi: 10.1371/journal.pone.0195123. eCollection 2018.

125

Serious infections in rheumatoid arthritis offspring exposed to tumour necrosis factor ? inhibitors: cohort study

Vinet É1,2, De Moura C2, Pineau CA1, Abrahamowicz M1, Curtis JR3, Bernatsky S1,2. Arthritis Rheumatol. 2018 May 17. doi: 10.1002/art.40536. [Epub ahead of print]

126

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab

Burmester GR1, Kaeley GS2, Kavanaugh AF3, Gabay C4, MacCarter DK5, Nash P6, Takeuchi T7, Goss SL8, Rodila R8, Chen K8, Kupper H9, Kalabic J9. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017.

127

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Kavanaugh A1, Kremer J2, Ponce L3, Cseuz R4, Reshetko OV5, Stanislavchuk M6, Greenwald M7, Van der Aa A8, Vanhoutte F8, Tasset C8, Harrison P8. Ann Rheum Dis. 2017 Jun;76(6):1009-1019. doi: 10.1136/annrheumdis-2016-210105. Epub 2016 Dec 19.

128

Rheumatoid Arthritis: Common Questions About Diagnosis and Management

Wasserman A1. Am Fam Physician. 2018 Apr 1;97(7):455-462.

129

Leg Length Inequality and Hip Osteoarthritis in the Multicenter Osteoarthritis Study and the Osteoarthritis Initiative

Kim C1, Nevitt M2, Guermazi A3, Niu J1, Clancy M1, Tolstykh I2, Jungmann PM4, Lane NE5, Segal NA6, Harvey WF7, Lewis CE8, Felson DT1,9. Arthritis Rheumatol. 2018 Apr 26. doi: 10.1002/art.40537. [Epub ahead of print]

130

Dysmobility Syndrome Independently Increases Fracture Risk in the Osteoporotic Fractures in Men (MrOS) Prospective Cohort Study

Buehring B1, Hansen KE1, Lewis BL1, Cummings SR2, Lane NE3, Binkley N1, Ensrud KE4, Cawthon PM2; Osteoporotic Fractures in Men (MrOS) Study Research Group. J Bone Miner Res. 2018 Apr 27. doi: 10.1002/jbmr.3455. [Epub ahead of print]

131

Associations between lean mass, muscle strength and power, and skeletal size, density and strength in older men

Chalhoub D1, Boudreau R2, Greenspan S2, Newman AB2, Zmuda J2, Frank-Wilson AW1, Nagaraj N2, Hoffman AR3, Lane NE4, Stefanick ML3, Barrett-Connor E5, Dam T5,6, Cawthon P7, Orwoll E8, Cauley JA2; Osteoporotic Fractures in Men (MrOS) Study Research Group.. J Bone Miner Res. 2018 Apr 27. doi: 10.1002/jbmr.3458. [Epub ahead of print]

132

Rheumatoid Arthritis: Common Questions About Diagnosis and Management

Wasserman A1. Am Fam Physician. 2018 Apr 1;97(7):455-462.

133

Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons

Chen B1, Zhao Y2, Cheng X3, Ma Y4, Chang EY5, Kavanaugh A6, Liu S7, Du J8. Magn Reson Imaging. 2018 Jun;49:4-9. doi: 10.1016/j.mri.2017.12.034. Epub 2018 Jan 5.

134

Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT)

Gulati AM1,2, Salvesen Ø3, Thomsen RS1,4, Kavanaugh A5, Semb AG6, Rollefstad S6, Haugeberg G7,8, Hoff M1,4. RMD Open. 2018 Mar 14;4(1):e000630. doi: 10.1136/rmdopen-2017-000630. eCollection 2018.

135

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Mease PJ1, Karki C2, Liu M2, Kavanaugh A3, Ritchlin CT4, Huynh DH5, Palmer JB6, Greenberg JD2,7. RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018.

136

Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions

Smith CJF1, Jones KL2, Johnson DL2, Bandoli G2, Robinson LK2, Kavanaugh A1, Chambers CD2. Am J Med Genet A. 2018 Mar;176(3):570-577. doi: 10.1002/ajmg.a.38594. Epub 2018 Jan 17.

137

Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from a Pharmacovigilance Safety Database

Clowse MEB1, Scheuerle AE2, Chambers C3, Afzali A4, Kimball AB5, Cush JJ6, Cooney M7, Shaughnessy L7, Vanderkelen M8, Förger F9. Arthritis Rheumatol. 2018 Apr 5. doi: 10.1002/art.40508. [Epub ahead of print]

138

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study

Pappas DA1,2, Nyberg F3,4, Kremer JM5, Lampl K6, Reed GW7,8, Horne L9, Ho M10, Onofrei A7, Malaviya AN11, Rillo OL12, Radominski SC13, Gal J14, Gibofsky A15, Popkova TV16, Laurindo L17, Kerzberg EM18, Zahora R19, Pons-Estel BA20, Curtis JR21, Furst DE22, Greenberg JD7,23. Clin Rheumatol. 2018 Apr 25. doi: 10.1007/s10067-018-4113-3. [Epub ahead of print]

139

Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis

Wells AF1, Greenwald M2, Bradley JD3, Alam J3, Arora V3, Kartman CE4. Rheumatol Ther. 2018 Apr 21. doi: 10.1007/s40744-018-0110-x. [Epub ahead of print]

140

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance

Ghosh N1, Ruderman EM2. Arthritis Res Ther. 2017 Dec 22;19(1):286. doi: 10.1186/s13075-017-1493-8.

141

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

Wells AF1, Edwards CJ2, Kivitz AJ3, Bird P4, Nguyen D5, Paris M5, Teng L5, Aelion JA6. Rheumatology (Oxford). 2018 Apr 4. doi: 10.1093/rheumatology/key032. [Epub ahead of print]

142

Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis

Quinn KA1,2, Ahlman MA3, Malayeri AA3, Marko J3, Civelek AC3, Rosenblum JS2, Bagheri AA2, Merkel PA4, Novakovich E2, Grayson PC2. Ann Rheum Dis. 2018 Apr 17. pii: annrheumdis-2018-213102. doi: 10.1136/annrheumdis-2018-213102. [Epub ahead of print]

143

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)

Winthrop KL1, Mariette X2, Silva JT3, Benamu E4, Calabrese LH5, Dumusc A6, Smolen JS7, Aguado JM8, Fernández-Ruiz M8. Clin Microbiol Infect. 2018 Feb 12. pii: S1198-743X(18)30150-2. doi: 10.1016/j.cmi.2018.02.002. [Epub ahead of print]

144

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment

Winthrop KL1, Korman N2, Abramovits W3, Rottinghaus ST4, Tan H4, Gardner A5, Mukwaya G6, Kaur M7, Valdez H6. J Am Acad Dermatol. 2018 Mar 1. pii: S0190-9622(17)32583-5. doi: 10.1016/j.jaad.2017.09.076. [Epub ahead of print]

145

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis

Papp KA1,2, Bachelez H3, Blauvelt A4, Winthrop KL5, Romiti R6, Ohtsuki M7, Acharya N8, Braun DK8, Mallbris L8, Zhao F8, Xu W8, Walls CD8, Strober B2,9. Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16.

146

Herpes zoster in psoriasis patients treated with tofacitinib

Winthrop KL1, Lebwohl M2, Cohen AD3, Weinberg JM2, Tyring SK4, Rottinghaus ST5, Gupta P5, Ito K5, Tan H5, Kaur M6, Egeberg A7, Mallbris L6, Valdez H8. J Am Acad Dermatol. 2017 Aug;77(2):302-309. doi: 10.1016/j.jaad.2017.03.023.

147

Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Sunderkötter CH1, Zelger B2, Chen KR3, Requena L4, Piette W5, Carlson JA6, Dutz J7, Lamprecht P8, Mahr A9, Aberer E10, Werth VP11, Wetter DA12, Kawana S13, Luqmani R14, Frances C15, Jorizzo J16, Watts JR17, Metze D18, Caproni M19, Alpsoy E20, Callen JP21, Fiorentino D22, Merkel PA23, Falk RJ24, Jennette JC24.

148

Health-related outcomes of importance to patients with Takayasu's arteritis

Sreih AG1, Alibaz-Oner F2, Easley E3, Davis T3, Mumcu G2, Milman N4, Robson J5, Direskeneli H2, Merkel PA6, Cronholm P3. Clin Exp Rheumatol. 2017 Sep 18. [Epub ahead of print]

149

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis

Robson JC1,2, Dawson J3, Cronholm PF4, Ashdown S5, Easley E6, Kellom KS7, Gebhart D8, Lanier G9, Milman N10, Peck J5, Luqmani RA11, Shea JA12, Tomasson G13, Merkel PA14. Rheumatol Int. 2018 Apr;38(4):675-682. doi: 10.1007/s00296-017-3855-6. Epub 2017 Nov 9.

150

18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis

Grayson PC1, Alehashemi S1, Bagheri AA1, Civelek AC2, Cupps TR3, Kaplan MJ1, Malayeri AA2, Merkel PA4, Novakovich E1, Bluemke DA2, Ahlman MA2. Arthritis Rheumatol. 2018 Mar;70(3):439-449. doi: 10.1002/art.40379. Epub 2018 Feb 6.

151

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Park JK1, Lee YJ2, Shin K3, Ha YJ2, Lee EY1, Song YW1, Choi Y4, Winthrop KL5, Lee EB1. Ann Rheum Dis. 2018 Mar 23. pii: annrheumdis-2018-213222. doi: 10.1136/annrheumdis-2018-213222. [Epub ahead of print]

152

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial

Kremer JM1, Rigby W2, Singer NG3, Birchwood C4, Gill D4, Reiss W4, Pei J4, Michalska M4. Arthritis Rheumatol. 2018 Mar 25. doi: 10.1002/art.40493. [Epub ahead of print]

153

Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities

Bacalao EJ1, Greene GJ2, Beaumont JL2, Eisenstein A2,3, Muftic A2, Mandelin AM1, Cella D2, Ruderman EM4. Clin Rheumatol. 2017 Aug;36(8):1729-1736. doi: 10.1007/s10067-017-3731-5. Epub 2017 Jun 26.

154

Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases

Shields KJ1, Mollnes TE2,3,4, Eidet JR5, Mikkelsen K6, Almdahl SM7, Bottazzi B8, Lyberg T5, Manzi S1, Ahearn JM1, Hollan I6,9,10,11. S One. 2017 Mar 31;12(3):e0174577. doi: 10.1371/journal.pone.0174577. eCollection 2017.

155

Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations

West SG1. Curr Opin Rheumatol. 2018 May;30(3):243-248. doi: 10.1097/BOR.0000000000000489

156

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Nash P1, Kirkham B2, Okada M3, Rahman P4, Combe B5, Burmester GR6, Adams DH7, Kerr L7, Lee C7, Shuler CL7, Genovese M8; SPIRIT-P2 Study Group. Collaborators (75) Ahmed K, Alper J, Barkham N, Bennett RE, García FJB, Alonso RB, Blumstein HB, Brooks MS, Burmester GR, Cagnoli P, Caldron PH, Cantagrel A, Chen DY, Churchill MA Jr, Codding CE, Combe B, Deane PMG, Del Giudice J, Deodhar AA, Dhar RK, Dokoupilova E, Egan RM, Everding A, Galíndez E, Genovese M, Goddard DH, Gottlieb A, Goupille P, Griffin RM, Gupta RC, Hall S, Hatti K, Howell MP, Huang YH, Jajoo R, Janssen NM, Kiltz U, Kivitz AJ, Klein SJ, Korkosz MP, Kotha R, Kremer JM, Lue C, de la Fuente JLM, Marzo-Ortega H, Masmitja JG, Mease PJ, Meroni PL, Mueller EC, Nandagudi AC, Nash P, Fernández-Nebro A, Neuwelt CM, Orbai AM, Oza MR, Parks DL, Pattanaik D, Rell-Bakalarska ME, Rosmarin D, Roussou E, Rychlewska-Hanczewksa AI, Sikes DH, Stack MT, Sunkureddi P, Tahir H, Thaçi D, Tsai TF, Turkiewicz AM, Unger L, Cabello RV, Wagner U, Wei CC, Wells AF, Youssef P, Zielinska A. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

157

Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients

Demoruelle MK1, Harrall KK1, Ho L1, Purmalek MM2, Seto NL2, Rothfuss HM3, Weisman MH4, Solomon JJ5, Fischer A1, Okamoto Y1, Kelmenson LB1, Parish MC1, Feser M1, Fleischer C1, Anderson C1, Mahler M6, Norris JM1, Kaplan MJ2, Cherrington BD3, Holers VM1, Deane KD1. Arthritis Rheumatol. 2017 Jun;69(6):1165-1175. doi: 10.1002/art.40066. Epub 2017 May 2.

158

Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases

Coates LC1,2, Tillett W3, Shaddick G4, Pincus T5, Kavanaugh A6, Helliwell PS1. Arthritis Care Res (Hoboken). 2017 Nov 7. doi: 10.1002/acr.23460. [Epub ahead of print]

159

Rheumatoid arthritis

Smolen JS1, Aletaha D1, Barton A2, Burmester GR3, Emery P4,5, Firestein GS6, Kavanaugh A6, McInnes IB7, Solomon DH8, Strand V9, Yamamoto K10. Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1.

160

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Genovese M1,2, Westhovens R3, Meuleners L4, Van der Aa A4, Harrison P4, Tasset C4, Kavanaugh A5. Arthritis Res Ther. 2018 Mar 23;20(1):57. doi: 10.1186/s13075-018-1541-z.

161

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone

Keystone EC1, Breedveld FC2, van der Heijde D2, van Vollenhoven RF3,4, Emery P5, Smolen JS6,7, Sainsbury I8, Florentinus S9, Kupper H10, Chen K11, Kavanaugh A12. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017.

162

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

Cohen S1, Curtis JR2, DeMasi R3, Chen Y4, Fan H4, Soonasra A5, Fleischmann R1,6. Rheumatol Ther. 2018 Feb 22. doi: 10.1007/s40744-018-0097-3. [Epub ahead of print]

163

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group

Fleischmann R1, Mease PJ2, Schwartzman S3, Hwang LJ4, Soma K5, Connell CA5, Takiya L6, Bananis E7. Clin Rheumatol. 2017 Jan;36(1):15-24. doi: 10.1007/s10067-016-3436-1. Epub 2016 Oct 12.

164

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Machado MAÁ1, Moura CS1, Guerra SF1, Curtis JR2, Abrahamowicz M1,3, Bernatsky S4,5. Arthritis Res Ther. 2018 Mar 23;20(1):60. doi: 10.1186/s13075-018-1539-6.

165

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept

Dehoratius RJ1,2, Brent LH3, Curtis JR4,5, Ellis LA1, Tang KL6. Patient. 2018 Feb 9. doi: 10.1007/s40271-018-0297-5. [Epub ahead of print]

166

Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes?

Curtis JR1,2, Yang S1, Singh JA1, Xie F1, Chen L1, Yun H1, Muntner P1, Kent ST1, Levitan EB1, Safford MM1, Saag KG1, Zhang J1,2. Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23535. [Epub ahead of print]

167

Evaluation of damage in giant cell arteritis

Kermani TA1, Sreih AG2, Cuthbertson D3, Carette S4, Hoffman GS5, Khalidi NA6, Koening CL7, Langford CA5, McAlear CA2, Monach PA8, Moreland L9, Pagnoux C4, Seo P10, Warrington KJ11, Ytterberg SR11, Merkel PA12; Vasculitis Clinical Research Consortium. Rheumatology (Oxford). 2018 Feb 1;57(2):322-328. doi: 10.1093/rheumatology/kex397.

168

Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist

Friedman MA1, Winthrop KL2. Rheum Dis Clin North Am. 2017 Feb;43(1):1-13. doi: 10.1016/j.rdc.2016.09.003. Epub 2016 Oct 22.

169

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017

Winthrop KL1, Strand V2, van der Heijde D3, Mease P4, Crow M5, Weinblatt M6, Bathon J7, Burmester GR8, Dougados M9, Kay J10, Mariette X11, Van Vollenhoven R12, Sieper J13, Melchers F14, Breedfeld FC15, Kalden J16, Smolen JS17, Furst DE18. Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.

170

Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Park JK1, Lee MA1, Lee EY1, Song YW1, Choi Y2, Winthrop KL3, Lee EB1. Ann Rheum Dis. 2017 Sep;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128. Epub 2017 May 3.

171

Transcriptional Profiling of Synovial Macrophages using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis

Mandelin AM 2nd1, Homan PJ1, Shaffer AM1, Cuda CM1, Dominguez ST1, Bacalao E1, Carns M1, Hinchcliff M1, Lee J2, Aren K1, Thakrar A1, Montgomery AB1, Louis Bridges S Jr.3, Bathon JM4, Atkinson JP5, Fox DA6, Matteson EL7, Buckley CD8, Pitzalis C9, Parks D5, Hughes LB3, Geraldino-Pardilla L4, Ike R6, Phillips K6, Wright K7, Filer A8, Kelly S9, Ruderman EM1, Morgan V1, Abdala-Valencia H1, Misharin AV10, Budinger GS10, Bartom ET11, Pope RM1, Perlman H1, Winter DR1. Arthritis Rheumatol. 2018 Feb 13. doi: 10.1002/art.40453. [Epub ahead of print]

172

"NETtling" the host: Breaking of tolerance in chronic inflammation and chronic infection

Skopelja-Gardner S1, Jones JD2, Rigby WFC3. J Autoimmun. 2018 Mar;88:1-10. doi: 10.1016/j.jaut.2017.10.008.

173

Review of Routine Laboratory Monitoring for Patients with Rheumatoid ArthritisReceiving Biologic or Nonbiologic DMARDs

Rigby WFC1, Lampl K2, Low JM3, Furst DE4,5,6. Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241. Epub 2017 Oct 31.

174

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial

Burmester GR1, Rigby WF2, van Vollenhoven RF3, Kay J4, Rubbert-Roth A5, Blanco R6, Kadva A7, Dimonaco S8. Ann Rheum Dis. 2017 Jul;76(7):1279-1284. doi: 10.1136/annrheumdis-2016-210561. Epub 2017 Apr 7.

175

Brief Report: Anti-Carbamylated Protein Antibodies in Rheumatoid ArthritisPatients Are Reactive With Specific Epitopes of the Human Fibrinogen ?-Chain

Jones JD1, Hamilton BJ2, Rigby WFC1. Arthritis Rheumatol. 2017 Jul;69(7):1381-1386. doi: 10.1002/art.40098. Epub 2017 Jun 5.

176

Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission

Pelzek AJ1, Grönwall C1, Rosenthal P1, Greenberg JD1, McGeachy M2, Moreland L2, Rigby WFC3, Silverman GJ1. Arthritis Rheumatol. 2017 Jun;69(6):1176-1186. doi: 10.1002/art.40053. Epub 2017 May 3.

177

Impact of vasculitis on employment and income

Barra L1, Borchin RL2, Burroughs C2, Casey GC3, McAlear CA4, Sreih AG4, Young K3, Merkel PA5, Pagnoux C6; Vasculitis Clinical Research Consortium and the Vasculitis Patient-Powered Research Network.. Clin Exp Rheumatol. 2018 Jan 10. [Epub ahead of print]

178

Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure

Robson JC1,2, Dawson J3, Cronholm PF4, Milman N5, Kellom KS6, Ashdown S7, Easley E8, Farrar JT9, Gebhart D10,11, Lanier G10,11, McAlear CA12, Peck J7, Luqmani RA7, Shea JA13, Tomasson G14, Merkel PA10,11. Patient Relat Outcome Meas. 2018 Jan 4;9:17-34. doi: 10.2147/PROM.S144992. eCollection 2018.

179

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Wallace ZS1, Miloslavsky EM1, Cascino M1, Unizony SH1, Lu N1, Hoffman GS2, Kallenberg CGM3, Langford CA2, Merkel PA4, Monach PA5, Seo P6, Spiera R7, St Clair EW8, Specks U9, Brunetta P10, Choi HK1, Stone JH1. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004-1010. doi: 10.1002/acr.23099.

180

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

Cornec D1,2, Kabat BF3, Mills JR4, Cheu M5, Hummel AM1, Schroeder DR3, Cascino MD5, Brunetta P5, Murray DL4, Snyder MR4, Fervenza F6, Hoffman GS7, Kallenberg CGM8, Langford CA7, Merkel PA9, Monach PA10, Seo P11, Spiera RF12, St Clair EW13, Stone JH14, Barnidge DR4, Specks U1. Rheumatology (Oxford). 2018 Jan 10. doi: 10.1093/rheumatology/kex484. [Epub ahead of print]

181

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

Merkel PA1, Xie G2, Monach PA3, Ji X4, Ciavatta DJ5, Byun J4, Pinder BD2, Zhao A2, Zhang J6, Tadesse Y2, Qian D4, Weirauch M7, Nair R8, Tsoi A8, Pagnoux C9, Carette S9, Chung S10, Cuthbertson D11, Davis JC Jr10, Dellaripa PF12, Forbess L13, Gewurz-Singer O8, Hoffman GS14, Khalidi N15, Koening C16, Langford CA14, Mahr AD17, McAlear C1, Moreland L18, Seo EP19, Specks U20, Spiera RF21, Sreih A1, St Clair EW22, Stone JH23, Ytterberg SR20, Elder JT24, Qu J25, Ochi T26, Hirano N26, Edberg JC27, Falk RJ5, Amos CI4, Siminovitch KA6; Vasculitis Clinical Research Consortium. Arthritis Rheumatol. 2017 May;69(5):1054-1066. doi: 10.1002/art.40034. Epub 2017 Apr 6.

182

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis

Rhee RL1, Davis JC2, Ding L2, Fervenza FC2, Hoffman GS2, Kallenberg CGM2, Langford CA2, McCune WJ2, Monach PA2, Seo P2, Spiera R2, St Clair EW2, Specks U2, Stone JH2, Merkel PA2. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.

183

The Pharmacogenomic Association of Fc? Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Cartin-Ceba R1, Indrakanti D2, Specks U1, Stone JH3, Hoffman GS4, Kallenberg CG5, Langford CA4, Merkel PA6, Spiera RF7, Monach PA8, St Clair EW9, Seo P10, Tchao NK11, Ytterberg SR1, Brunetta PG12, Song H2, Birmingham D2, Rovin BH2; RAVE-Immune Tolerance Network Research Group. Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822.

184
185

Economic impact of biologic utilization patterns in patients with psoriatic arthritis

Schwartzman S1, Li Y2, Zhou H3, Palmer JB2. Clin Rheumatol. 2017 Jul;36(7):1579-1588. doi: 10.1007/s10067-017-3636-3. Epub 2017 May 4.

186

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Kay J1, Schoels MM2, Dörner T3, Emery P4, Kvien TK5, Smolen JS2,6, Breedveld FC7; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2.

187

Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton

Dubrovsky AM1, Lim MJ1,2, Lane NE3,4. Calcif Tissue Int. 2018 Feb 22. doi: 10.1007/s00223-018-0401-9. [Epub ahead of print]

188

Sex dimorphic regulation of osteoprogenitor progesterone in bone stromal cells

Kot A1, Zhong ZA1,2, Zhang H1,3, Lay YE1, Lane NE1, Yao W4. J Mol Endocrinol. 2017 Nov;59(4):351-363. doi: 10.1530/JME-17-0076. Epub 2017 Sep 4.

189

Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study

Gourlay ML1, Ritter VS2, Fine JP2, Overman RA3, Schousboe JT4,5, Cawthon PM6, Orwoll ES7, Nguyen TV8,9, Lane NE10, Cummings SR6, Kado DM11,12, Lapidus JA13, Diem SJ14,15, Ensrud KE14,15,16; Osteoporotic Fractures in Men (MrOS) Study Group. Arch Osteoporos. 2017 Oct 20;12(1):91. doi: 10.1007/s11657-017-0389-1.

190

Patterns and Predictors of Frailty Transitions in Older Men: The Osteoporotic Fractures in Men Study

Pollack LR1, Litwack-Harrison S2,3, Cawthon PM2,3, Ensrud K4, Lane NE5, Barrett-Connor E6, Dam TT1,7. J Am Geriatr Soc. 2017 Nov;65(11):2473-2479. doi: 10.1111/jgs.15003. Epub 2017 Sep 5.

191

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

Buckley L1, Guyatt G2, Fink HA3, Cannon M4, Grossman J5, Hansen KE6, Humphrey MB7, Lane NE8, Magrey M9, Miller M10, Morrison L11, Rao M12, Byun Robinson A13, Saha S6, Wolver S14, Bannuru RR12, Vaysbrot E12, Osani M12, Turgunbaev M15, Miller AS15, McAlindon T12. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095-1110. doi: 10.1002/acr.23279. Epub 2017 Jun 6.

192

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Wallace ZS1, Miloslavsky EM1, Cascino M1, Unizony SH1, Lu N1, Hoffman GS2, Kallenberg CGM3, Langford CA2, Merkel PA4, Monach PA5, Seo P6, Spiera R7, St Clair EW8, Specks U9, Brunetta P10, Choi HK1, Stone JH1. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004-1010. doi: 10.1002/acr.23099.

193

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

Cornec D1,2, Kabat BF3, Mills JR4, Cheu M5, Hummel AM1, Schroeder DR3, Cascino MD5, Brunetta P5, Murray DL4, Snyder MR4, Fervenza F6, Hoffman GS7, Kallenberg CGM8, Langford CA7, Merkel PA9, Monach PA10, Seo P11, Spiera RF12, St Clair EW13, Stone JH14, Barnidge DR4, Specks U1. Rheumatology (Oxford). 2018 Jan 10. doi: 10.1093/rheumatology/kex484. [Epub ahead of print]

194

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

Merkel PA1, Xie G2, Monach PA3, Ji X4, Ciavatta DJ5, Byun J4, Pinder BD2, Zhao A2, Zhang J6, Tadesse Y2, Qian D4, Weirauch M7, Nair R8, Tsoi A8, Pagnoux C9, Carette S9, Chung S10, Cuthbertson D11, Davis JC Jr10, Dellaripa PF12, Forbess L13, Gewurz-Singer O8, Hoffman GS14, Khalidi N15, Koening C16, Langford CA14, Mahr AD17, McAlear C1, Moreland L18, Seo EP19, Specks U20, Spiera RF21, Sreih A1, St Clair EW22, Stone JH23, Ytterberg SR20, Elder JT24, Qu J25, Ochi T26, Hirano N26, Edberg JC27, Falk RJ5, Amos CI4, Siminovitch KA6; Vasculitis Clinical Research Consortium. Arthritis Rheumatol. 2017 May;69(5):1054-1066. doi: 10.1002/art.40034. Epub 2017 Apr 6.

195

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis

Rhee RL1, Davis JC2, Ding L2, Fervenza FC2, Hoffman GS2, Kallenberg CGM2, Langford CA2, McCune WJ2, Monach PA2, Seo P2, Spiera R2, St Clair EW2, Specks U2, Stone JH2, Merkel PA2. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.

196

The Pharmacogenomic Association of Fc? Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Cartin-Ceba R1, Indrakanti D2, Specks U1, Stone JH3, Hoffman GS4, Kallenberg CG5, Langford CA4, Merkel PA6, Spiera RF7, Monach PA8, St Clair EW9, Seo P10, Tchao NK11, Ytterberg SR1, Brunetta PG12, Song H2, Birmingham D2, Rovin BH2; RAVE-Immune Tolerance Network Research Group. Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822.

197

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

Ferreira I1, Croca S1, Raimondo MG1, Matharu M2, Miller S2, Giles I1, Isenberg D1,3, Ioannou Y1,3, Hanly JG4, Urowitz MB5, Anderson N5, Aranow C6, Askanase A7, Bae SC8, Bernatsky S9, Bruce IN10, Buyon J11, Clarke AE12, Dooley MA13, Fortin P14, Ginzler E15, Gladman D5, Gordon C16, Inanc M17, Jacobsen S18, Kalunian K19, Kamen D20, Khamashta M21, Lim S22, Manzi S23, Merrill J24, Nived O25, Peschken C26, Petri M27, Ramsey-Goldman R28, Ruiz-Irastorza G29, Sanchez-Guerrero J30, Steinson K31, Sturfelt GK25, van Vollenhoven R32, Wallace DJ33, Zoma A34, Rahman A35. Arthritis Res Ther. 2017 Dec 22;19(1):287. doi: 10.1186/s13075-017-1495-6.

198

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort

Little J1,2, Parker B2, Lunt M1, Hanly JG3, Urowitz MB4, Clarke AE5, Romero-Diaz J6, Gordon C7,8, Bae SC9, Bernatsky S10, Wallace DJ11, Merrill JT12, Buyon J13, Isenberg DA14, Rahman A14, Ginzler EM15, Petri M16, Dooley MA17, Fortin P18, Gladman DD4, Steinsson K19, Ramsey-Goldman R20, Khamashta MA21, Aranow C22, Mackay M22, Alarcón GS23, Manzi S24, Nived O25, Jönsen A25, Zoma AA26, van Vollenhoven RF27, Ramos-Casals M28, Ruiz-Irastorza G29, Sam Lim S30, Kalunian KC31, Inanc M32, Kamen DL33, Peschken CA34, Jacobsen S35, Askanase A36, Sanchez-Guerrero J37, Bruce IN1,2. Rheumatology (Oxford). 2018 Jan 18. doi: 10.1093/rheumatology/kex444. [Epub ahead of print]

199

Cerebrovascular Events in Systemic Lupus Erythematosus

Hanly JG1, Li Q2, Su L2, Urowitz MB3, Gordon C4, Bae SC5, Romero-Diaz J6, Sanchez-Guerrero J3, Bernatsky S7, Clarke AE8, Wallace DJ9, Isenberg DA10, Rahman A10, Merrill JT11, Fortin P12, Gladman DD3, Bruce IN13,14, Petri M15, Ginzler EM16, Dooley MA17, Steinsson K18, Ramsey-Goldman R19, Zoma AA20, Manzi S21, Nived O22, Jonsen A22, Khamashta MA23, Alarcón GS24, Chatham W24, van Vollenhoven RF25, Aranow C26, Mackay M26, Ruiz-Irastorza G27, Ramos-Casals M28, Lim SS29, Inanc M30, Kalunian KC31, Jacobsen S32, Peschken CA33, Kamen DL34, Askanase A35, Theriault C36, Farewell V2. Arthritis Care Res (Hoboken). 2018 Jan 5. doi: 10.1002/acr.23509. [Epub ahead of print]

200

Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls

Poornima IG1, Shields K2, Kuller LH3, Manzi SM2, Ramsey-Goldman R4, Richardson C5, Rhew E6, Dunlop DD7, Song J8, Edmundowicz D9, Kondos GT10, Carr JJ11, Langman CB12, Price H13, Chung AH4, Santelices LB2, Mackey RH14. Lupus. 2018 Jan 1:961203317751060. doi: 10.1177/0961203317751060. [Epub ahead of print]

201

Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification

Ahearn JM1, Liu CC1, Manzi S1. Expert Rev Clin Immunol. 2017 Dec;13(12):1133-1142. doi: 10.1080/1744666X.2017.1392238. Epub 2017 Nov 6.

202

A North American perspective of content and quality of websites in the English language on childhood-onset lupus erythematosus

Cutler C1, Peng T2, Stinson J3, Tucker L4, Boneparth A1, Klein Gitelman M5, Moorthy LN1. Lupus. 2017 Jan 1:961203317746246. doi: 10.1177/0961203317746246. [Epub ahead of print]

203

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register

McCarthy EM1, Sutton E2, Nesbit S2, White J2, Parker B1,3, Jayne D4, Griffiths B5, Isenberg DA6, Rahman A6, Gordon C7,8, D'Cruz DP9, Rhodes B10, Lanyon P11, Vital EM12,13, Yee CS14, Edwards CJ15,16, Teh LS17, Akil M18, McHugh NJ19,20, Zoma A21, Bruce IN1,2. Rheumatology (Oxford). 2017 Dec 5. doi: 10.1093/rheumatology/kex395. [Epub ahead of print]

204

Epidemiology of systemic lupus erythematosus: an update

Stojan G1, Petri M. Curr Opin Rheumatol. 2017 Dec 14. doi: 10.1097/BOR.0000000000000480. [Epub ahead of print]

205

Understanding the role of environmental factors in the development of systemic lupus erythematosus

Parks CG1, de Souza Espindola Santos A2, Barbhaiya M3, Costenbader KH4. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):306-320. doi: 10.1016/j.berh.2017.09.005. Epub 2017 Oct 21.

206

The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus

Pentony P1, Duquenne L1, Dutton K1, Mankia K1, Gul H1, Vital E1, Emery P1. Discov Med. 2017 Nov;24(133):191-200.

207

Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis

Legge A1, Blanchard C1, Hanly JG2,3. Open Access Rheumatol. 2017 Nov 8;9:191-200. doi: 10.2147/OARRR.S148376. eCollection 2017.

208

Lupus Nephritis: Current Treatment Paradigm and Unmet Needs

Menez SP1, El Essawy B2, Atta MG1. Rev Recent Clin Trials. 2017 Nov 22. doi: 10.2174/1574887112666171123113200. [Epub ahead of print]

209

Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus

Martin M1, Smol?g KI1, Björk A1, Gullstrand B2, Okrój M3, Leffler J4, Jönsen A2, Bengtsson AA2, Blom AM5. Arthritis Res Ther. 2017 Dec 6;19(1):266. doi: 10.1186/s13075-017-1470-2.

210

Epilepsy among Systemic Lupus Erythematosus Patients: Insights from a Large Database Analysis

Watad A1,2,3, Tiosano S1,3, Bragazzi NL4, Brigo F5, Comaneshter D6, Cohen AD6,7, Amital H1,2,3. Neuroepidemiology. 2017 Dec 1;50(1-2):1-6. doi: 10.1159/000485136. [Epub ahead of print]

211

Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach

Barber MRW1, Hanly JG2, Su L3, Urowitz MB4, Pierre YS5, Romero-Diaz J6, Gordon C7, Bae SC8, Bernatsky S9, Wallace DJ10, Isenberg DA11, Rahman A11, Ginzler EM12, Petri M13, Bruce IN14,15, Fortin PR16, Gladman DD4, Sanchez-Guerrero J4, Ramsey-Goldman R17, Khamashta MA18, Aranow C19, Mackay M19, Alarcón GS20, Manzi S21, Nived O22, Jönsen A22, Zoma AA23, van Vollenhoven RF24, Ramos-Casals M25, Ruiz-Irastorza G26, Sam Lim S27, Kalunian KC28, Inanc M29, Kamen DL30, Peschken CA31, Jacobsen S32, Askanase A33, Theriault C34, Farewell V3, Clarke AE35. Arthritis Care Res (Hoboken). 2017 Nov 28. doi: 10.1002/acr.23480. [Epub ahead of print]

212

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

van Vollenhoven RF1, Keystone EC2, Strand V3, Pacheco-Tena C4, Vencovský J5, Behrens F6, Racewicz A7, Zipp D8, Rharbaoui F8, Wolter R8, Knierim L8, Schmeidl R8, Zhou X8, Aigner S8, Dälken B8, Wartenberg-Demand A8; TREAT2b study team. Collaborators (99) Aelion J, Arreola JA, Arias MA, Back J, Baranauskaite A, Behrens F, Bennett R, Bookman A, Brzezicki J, Butrimiene I, Churchill M, Djacenko S, Dokoupilova E, Drescher E, Dudek A, Edwards W, Eliseeva L, Ershova O, Fortin I, Galatikova D, De la Torre IG, Garmish O, Gasanov Y, Gnylorybov A, Goldberg M, Golovchenko O, Gordeev I, Hiepe F, Sil GH, Husarova V, Iaremenko O, Jeka S, Kamburova D, Kavanaugh A, Keszthelyi P, Keystone E, Knyazeva L, Krechikova D, Kuzmanova S, Lapcikova A, Levinson D, Lopez Garcia JA, Lymar I, Marinova N, Moiseev S, Musilova L, Nagy M, Najam S, Nedovic J, Nemeth E, Novosad L, Ochoa-Ortega L, Oparanov B, Tena CP, Penev D, Pesant Y, Podrazilova L, Pulka G, Racewicz A, Raskina T, Rekalov D, Reshetko O, Riega Torres JC, Rubbert-Roth A, Rychlewska-Hanczewska A, Savina L, Schulze-Koops H, Bukilica MS, Shevchuk S, Simoncsics E, Simova L, Sitek-Ziolkowska K, Skublova A, Sliwowska B, Smakotina S, Spieler W, Stanislavchuk M, Stefanovic D, Stejfova Z, Stoilov R, Strapkova M, Stryuk R, Sulyok G, Sylwestrzak A, Szombati I, Theander J, Tomkova S, Trapp R, Tseluyko V, Tälli J, Vencovsky J, Vitek P, Vladeva S, Vo J, Vollenhoven RV, Vujasinovic-Stupar N, Wassenberg S, Wollenhaupt J, Zielinska A. Ann Rheum Dis. 2018 Jan 17. pii: annrheumdis-2017-212478. doi: 10.1136/annrheumdis-2017-212478. [Epub ahead of print]

213

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

Strand V1, Michalska M2, Birchwood C2, Pei J2, Tuckwell K3, Finch R4, Gabay C5, Kavanaugh A6, Jones G7. RMD Open. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496. eCollection 2017.

214

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis

Kavanaugh A1, van Vollenhoven RF2, Fleischmann R3, Emery P4,5, Sainsbury I6, Florentinus S6, Chen S6, Guérette B6, Kupper H7, Smolen JS8. Ann Rheum Dis. 2018 Feb;77(2):289-292. doi: 10.1136/annrheumdis-2017-211871. Epub 2017 Nov 16.

215

Understanding the determinants of health-related quality of life in rheumatoidarthritis-associated interstitial lung disease

Natalini JG1, Swigris JJ2, Morisset J1, Elicker BM3, Jones KD4, Fischer A5, Collard HR1, Lee JS6. Respir Med. 2017 Jun;127:1-6. doi: 10.1016/j.rmed.2017.04.002. Epub 2017 Apr 5.

216

Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis

Curtis JR1,2, Chen L3,4, Danila MI3,4, Saag KG3,4, Parham KL3,4, Cush JJ3,4. J Rheumatol. 2018 Jan;45(1):40-44. doi: 10.3899/jrheum.170548. Epub 2017 Nov 15.

217

Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators

Sparks JA1, Chang SC1, Nguyen US2, Barbhaiya M1, Tedeschi SK1, Lu B1, Kreps DJ1, Costenbader KH1, Zhang Y3, Choi HK3, Karlson EW1. Arthritis Rheumatol. 2018 Jan;70(1):18-29. doi: 10.1002/art.40346. Epub 2017 Dec 7.

218

Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study

Schulman E1, Bartlett SJ2, Schieir O3, Andersen KM1, Boire G4, Pope JE5, Hitchon C6, Jamal S7, Thorne CJ8, Tin D8, Keystone EC9, Haraoui B10, Goodman SM1, Bykerk VP1,9, Investigators C. Arthritis Care Res (Hoboken). 2017 Nov 30. doi: 10.1002/acr.23457. [Epub ahead of print]

219

Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis

Young BL1, Watson SL1, Perez JL1, McGwin G1, Singh JA1, Ponce BA1. J Rheumatol. 2017 Dec 1. pii: jrheum.170001. doi: 10.3899/jrheum.170001. [Epub ahead of print]

220

Lessons Learned from Imaging on Rheumatoid Arthritis

Antonietta D'Agostino M1. Isr Med Assoc J. 2017 Nov;19(11):703-707.

221

A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States

Spivey CA1, Griffith J2, Kaplan C3, Postlethwaite A3, Ganguli A2, Wang J4. Rheumatol Ther. 2017 Dec 4. doi: 10.1007/s40744-017-0089-8. [Epub ahead of print]

222
223

Systemic lupus erythematosus observations of travel burden: A qualitative inquiry

Williams EM1, Ortiz K2, Flournoy-Floyd M1, Bruner L3, Kamen D4. Int J Rheum Dis. 2015 Jul 14. doi: 10.1111/1756-185X.12614. [Epub ahead of print]

224

Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis

Bredemeier M1, Campos GG, de Oliveira FK. Clin Rheumatol. 2015 Jun 12. [Epub ahead of print]

225

Foot problems in people with gout in primary care: baseline findings from a prospective cohort study

Roddy E1, Muller S1, Rome K2, Chandratre P1, Hider SL1, Richardson J1, Blagojevic-Bucknall M1, Mallen CD1. J Foot Ankle Res. 2015 Jul 23;8:31. doi: 10.1186/s13047-015-0090-9. eCollecARTHROS_RA_Bredemeier07272015-105949|Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis~Bredemeier M1, Campos GG, de Oliveira FK. Clin Rheumatol. 2015 Jun 12. [Epub ahead of print]

226

Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy

Garcia C1, Lyon L2, Conell C2, Littell RD1, Powell CB3. Gynecol Oncol. 2015 Jun 16. pii: S0090-8258(15)30042-1. doi: 10.1016/j.ygyno.2015.06.020. [Epub ahead of print]

227

Impact of obesity on disability, function, and physical activity: data from the Osteoarthritis Initiative

Batsis JA1, Zbehlik AJ, Barre LK, Bynum J, Pidgeon D, Bartels SJ. Scand J Rheumatol. 2015 Jun 17:1-8. [Epub ahead of print]

228

Hyponatremia is Associated with Increased Osteoporosis and Bone Fractures in a Large U. S. Health System Population

Miriam Rachel Usala G1, Fernandez SJ2, Mete M2, Cowen L3, Shara NM2, Barsony J3, Verbalis JG3. J Clin Endocrinol Metab. 2015 Jun 17:jc20151261. [Epub ahead of print]

229

Mortality after distal radial fractures in the Medicare population

Shauver MJ1, Zhong L1, Chung KC2. J Hand Surg Eur Vol. 2015 Jun 17. pii: 1753193415589735. [Epub ahead of print

230

Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study

Seo GH1, Choi HJ2. J Bone Metab. 2015 May;22(2):77-81. doi: 10.11005/jbm.2015.22.2.77. Epub 2015 May 31.

231

Weight changes after total hip or knee arthroplasty: prevalence, predictors, and effects on outcomes

Ast MP1, Abdel MP1, Lee YY1, Lyman S1, Ruel AV1, Westrich GH1. J Bone Joint Surg Am. 2015 Jun 3;97(11):911-9. doi: 10.2106/JBJS.N.00232.

232

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty

Arden N1, Richette P, Cooper C, Bruyère O, Abadie E, Branco J, Brandi ML, Berenbaum F, Clerc C, Dennison E, Devogelaer JP, Hochberg M, D'Hooghe P, Herrero-Beaumont G, Kanis JA, Laslop A, Leblanc V, Maggi S, Mautone G, Pelletier JP, Petit-Dop F, Reiter-Niesert S, Rizzoli R, Rovati L, Tajana Messi E, Tsouderos Y, Martel-Pelletier J, Reginster JY. Drugs Aging. 2015 Jun 18. [Epub ahead of print]

233

ABCs of Evidence-based Anterior Cruciate Ligament Injury Prevention Strategies in Female Athletes

Sugimoto D1, Myer GD2, Micheli LJ3, Hewett TE4. Curr Phys Med Rehabil Rep. 2015 Mar 1;3(1):43-49.

234

Physical function, hyperuricemia and gout in older adults enrolled in the atherosclerosis risk in communities cohort study

Burke BT1, Köttgen A1,2, Law A3, Windham BG4, Segev D3, Baer AN5, Coresh J1, McAdams-DeMarco MA1,3. Arthritis Care Res (Hoboken). 2015 Jul 2. doi: 10.1002/acr.22648. [Epub ahead of print]

235

Does a family history of RA influence the clinical presentation and treatment response in RA?

Frisell T1, Saevarsdottir S2, Askling J3. Author information Ann Rheum Dis. 2015 Jun 19. pii: annrheumdis-2015-207670. doi: 10.1136/annrheumdis-2015-207670. [Epub ahead of print]

236

Medication Adherence in Patients with Rheumatoid Arthritis: The Effect of Patient Education, Health Literacy, and Musculoskeletal Ultrasound

Joplin S1, van der Zwan R2, Joshua F3, Wong PK4. Biomed Res Int. 2015;2015:150658. Epub 2015 Apr 28.

237

The optimal combination therapy for the treatment of early rheumatoid arthritis

De Cock D1, Van der Elst K, Meyfroidt S, Verschueren P, Westhovens R. Expert Opin Pharmacother. 2015 Aug;16(11):1615-25. doi: 10.1517/14656566.2015.1056735. Epub 2015 Jun 10.

238

Predictors of arthritis in pediatric patients with lupus

Sule SD1, Moodalbail DG2, Burnham J3, Fivush B4, Furth SL5,6. Pediatr Rheumatol Online J. 2015 Jul 14;13(1):30. doi: 10.1186/s12969-015-0027-7

239

Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact-A systematic literature review

Carli L1, Tani C2, Vagnani S2, Signorini V2, Mosca M3. Semin Arthritis Rheum. 2015 May 21. pii: S0049-0172(15)00115-8. doi: 10.1016/j.semarthrit.2015.05.009. [Epub ahead of print]

240

A highlight from the LUPUS 2014 meeting: eight great ideas

Buyon JP1, Cohen P2, Merrill JT3, Gilkeson G4, Kaplan M5, James J6, McCune WJ7, Bernatsky S8, Elkon K9. Lupus Sci Med. 2015 Jun 30;2(1):e000087. doi: 10.1136/lupus-2015-000087. eCollection 2015.

241

Juvenile spondyloarthritis

1aDivision of Rheumatology, The Children's Hospital of Philadelphia bDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

242

Biomarkers in axial spondyloarthritis

Maksymowych WP1. Curr Opin Rheumatol. 2015 Jul;27(4):343-8. doi: 10.1097/BOR.0000000000000180.

243

A rheumatology perspective on cutaneous vasculitis: assessment and investigation for the non-rheumatologist

Rawlings CR1, Fremlin GA, Nash J, Harding K. Int Wound J. 2015 Mar 26. doi: 10.1111/iwj.12437. [Epub ahead of print]

244

Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis

Sieper J1, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landewé R. Arthritis Care Res (Hoboken). 2015 Apr 1. doi: 10.1002/acr.22594. [Epub ahead of print]

245

Patient Information about Gout: An International Review of Existing Educational Resources

Johnston ME1, Treharne GJ1, Chapman PT1, Stamp LK1. J Rheumatol. 2015 Apr 1. pii: jrheum.141442. [Epub ahead of print]

246

Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout

Wang L1, Sawhney M2, Zhao Y3, Carpio GR4, Fonseca V5, Shi L6. Clin Ther. 2015 Apr 6. pii: S0149-2918(15)00147-2. doi: 10.1016/j.clinthera.2015.03.010. [Epub ahead of print]